Induction of final follicle maturation with a gonadotropin-releasing hormone agonist in women at risk of ovarian hyperstimulation syndrome undergoing gonadotropin stimulation and intrauterine insemination: Proof-of-concept study

Clinical and Experimental Obstetrics and Gynecology

Volumn 39, Issue 4, 2012, Pages 436-439

  Awwad, J T ^a   Hannoun, A B ^a   Khalil, A ^a   Younes, Z M H ^a   Ghazeeri, G S ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Follicle maturation; Gonadotropin releasing hormone agonist; Intrauterine insemination; Multiple gestations; Ovarian hyperstimulation syndrome

Indexed keywords

GONADORELIN AGONIST; TRIPTORELIN;

ADULT; ARTICLE; CLINICAL ARTICLE; FEAR; FEMALE; HUMAN; INTRAUTERINE INSEMINATION; OVARY FOLLICLE MATURATION; OVARY HYPERSTIMULATION; PREGNANCY RATE; REPEATED DRUG DOSE; SPONTANEOUS ABORTION;

ADULT; FEMALE; FERTILITY AGENTS, FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INSEMINATION, ARTIFICIAL; MENOTROPINS; OVARIAN FOLLICLE; OVARIAN HYPERSTIMULATION SYNDROME; PREGNANCY; PREGNANCY, MULTIPLE; TRIPTORELIN PAMOATE;

EID: 84872744892     PISSN: 03906663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Engmann L., DiLuigi A., Schmidt D., Nulsen J., Maier D., Benadiva C.: "The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study". Fertil. Steril., 2008, 89, 84.
2. Manzanares M.A., Gómez-Palomares J.L., Ricciarelli E., Hernández E.R.: "Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels". Fertil. Steril., 2010, 93, 1215.
3. Humaidan P., Bredkjaer H.E., Bungum L., Bungum M., Grondahl M.L., Westergaard L. et al.: "GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study". Hum. Reprod., 2005, 20, 1213.
4. Kolibianakis E.M., Schultze-Mosgau A., Schroer A., van Steirteghem A., Devroey P., Diedrich K. et al.: "A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists". Hum. Reprod., 2005, 20, 2887.
5. Griesinger G., Diedrich K., Devroey P., Kolibianakis E.M.: "GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis". Hum. Reprod. Update, 2006, 12, 159.
6. Bomsel-Helmreich O., Vu N Huyen L., Durand-Gasselin I.: "Effects of varying doses of HCG on the evolution of preovulatory rabbit follicles and oocytes". Hum. Reprod., 1989, 4, 636.
7. Peluso J.J.: "Role of the amplitude of the gonadotropin surge in the rat". Fertil. Steril., 1990, 53, 150.
8. Olivennes F., Fanchin R., Bouchard P., Taieb J., Frydman R.: "Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist". Fertil. Steril., 1996, 66, 151.
9. Pirard C., Donnez J., Loumaye E.: "GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin". Hum. Reprod., 2005, 20, 1798.
10. Van der Meer S., Gerris J., Joostens M., Tas B.: "Triggering of ovulation using a gonadotrophin-releasing hormone agonist does not prevent ovarian hyperstimulation syndrome". Hum. Reprod., 1993, 8, 1628.
11. Navot D., Bergh P.A., Laufer N.: "Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment". Fertil. Steril., 1992, 58, 249.
12. Babayof R, Margalioth E.J., Huleihel M., Amash A., Zylber-Haran E., Gal M. et al.: "Serum inhibin A, VEGF and TNF alpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial". Hum. Reprod., 2006, 21, 1260.
13. Acevedo B., Gomez-Palomares J.L., Ricciarelli E., Hernandez E.R.: "Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates". Fertil. Steril., 2006, 86, 1682.
14. Itskovitz J., Boldes R., Levron J., Erlik Y., Kahana L., Brandes J.M.: "Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist". Fertil. Steril., 1991, 56, 213.
15. Nevo O., Eldar-Geva T., Kol S., Itskovitz-Eldor J.: "Lower levels of inhibin A and pro--C during the luteal phase after triggering oocyte maturation with a gonadotropin releasing hormone agonist versus human chorionic gonadotropin". Fertil. Steril., 2003, 79, 1123.
16. Yano T., Yano N., Matsumi H., Morita Y., Tsutsumi O., Schally A.V., Taketani Y.: "Effect of luteinizing hormone-releasing hormone analogs on the rat ovarian follicle development". Horm. Res., 1997, 48, 35.
17. Takekida S., Deguchi J., Samoto T., Matsuo H., Maruo T.: "Comparative analysis of the effects of gonadotropin-releasing hormone agonist on the proliferative activity, apoptosis and steroidogenesis in cultured porcine granulosa cells at varying stages of follicular growth". Endocrine, 2000, 12, 61.
18. Fauser B.C., de Jong D., Olivennes F., Wramsby H., Tay C., Itskovitz-Eldor J. et al.: "Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization". J. Clin. Endocrinol. Metab., 2002, 87, 709.
19. Andersen C.Y., Humaidan P., Ejdrup H.B., Bungum L., Grondahl M.L., Westergaard L.G.: "Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction". Hum. Reprod., 2006, 21, 2126.
20. Beckers N.G., Macklon N.S., Eijkemans M.J., Ludwig M., Felberbaum R.E., Diedrich K. et al.: "Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment". J. Clin. Endocrinol. Metab., 2003, 88, 4186.